Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal - Wikidata - awgldk - TriplyDB

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

http://www.wikidata.org/entity/Q34147299

about

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis Protection against the Metabolic Syndrome by Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated Receptor γ and Glucagon-Like Peptide-1 Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle.Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance Breakfast frequency and quality may affect glycemia and appetite in adults and children.Beta-cell deterioration--prospects for reversal or prevention.Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice.Glucose metabolism and cardiac hypertrophy Glucose effectiveness in obese children: relation to degree of obesity and dysglycemia.A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes The GLP-1 system as a therapeutic target.Glucagon-like peptide 1 (GLP-1) and metabolic diseases.Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcinoembryonic Antigen-related Cell Adhesion Molecule 2 (CEACAM2).Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids.Exenatide can reduce glucose independent of islet hormones or gastric emptying.Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.FGF19 action in the brain induces insulin-independent glucose lowering Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats Cooperation between brain and islet in glucose homeostasis and diabetes.Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.The structure and function of the glucagon-like peptide-1 receptor and its ligands Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.

P2860

Q24629441-6B48B365-AA8A-4173-917D-370E1DD724C3 Q26852743-28ABB49C-5EC5-40C2-B12F-F17BFB7E3F06 Q27321785-A282F653-2FAE-445C-A55C-95BC25B92E9E Q28306665-30F6F905-8386-4A03-A6D1-856AC878ECC6 Q30418716-FC2FDE48-4E17-4C47-A71E-1DF9AD86C83E Q33367023-85B6DF70-2B15-4742-8CC3-258309FCF7CD Q33800196-2604D8E0-5D02-41A8-AE8C-3CA14E5D65E8 Q33826388-352FA8C7-7303-4B42-BF69-57E8F481B81B Q33925948-DB97537B-3C2A-44BF-8247-2B7496FF8656 Q34026346-BE164671-2CC2-4B86-8789-D3C1806AA1B0 Q34157515-E0044909-9FC0-46FB-9243-32AD190B8BAF Q34402292-6A5955D9-1B9A-4B0C-B3C6-74F60969B93F Q34422778-EF5B8D1B-3E2D-47CA-93B2-1AA588CE7546 Q34687550-F28C6FC8-55BD-4788-A56F-41A7354C993B Q34808553-EFF5A6EC-8F36-4709-91CF-93D32F561632 Q35207924-56E73BB8-2623-487B-94A4-13AB0C72ADE1 Q35643633-E8D38FAC-FFA9-45D0-9E32-E6128435A93B Q35757217-6907993B-8917-4BDC-AE97-5E9C5A269FC5 Q35772029-8FE295A8-4A1A-4036-B03A-6CD440E2F01C Q35801801-1335FCFF-A12C-447E-B9B4-85B001772339 Q36017369-129DB0DC-3D20-493F-9BF1-A86604E014D9 Q36265221-49FA3127-F05B-499B-ADF4-4BBC6CDB5BB5 Q36309183-F1A09B31-8799-43F0-BB00-23403E2DC022 Q36442462-189ABA4A-244B-420F-B06D-0C68B89B2F01 Q36465496-D28673DB-4B2F-46DD-B7AC-FEA1491FED30 Q36731945-A068FFE2-8095-420F-94F5-E280F0CFD520 Q36736464-FE4DC1BE-A599-4AAC-9D95-9CB9A668808F Q36846123-71E6A317-5E10-4866-B7EB-B39222C9BCD2 Q37051107-5F664697-4EF4-4632-8FF5-980DC2BD9406 Q37091579-0E880F7B-45F7-4920-9AFC-ACBD586043A0 Q37125933-CCDDC093-B4F0-4563-8121-FAFCBCB21546 Q37259301-0C2B52D3-5AC5-4F98-998F-7B722767A275 Q37345249-CABEA7E1-CDAF-447B-BB58-41CC307F38B8 Q37351161-4334B6C6-6712-4CCE-813B-64EDCA5FCB77 Q37510130-9E616929-7B73-4976-AADA-A5192E55BB48 Q37698362-C9660E67-5815-47D7-9FAA-6421E42BDA9B Q37704721-F793C90F-3CAF-434D-8DD6-D2AABACD9F66 Q37847181-8347FE59-5D57-4D77-8D31-6695EB659CEF Q37939244-C8A3B489-D55B-449C-953A-054DEF630EA1 Q38110890-18A8CB2F-7F72-4A80-A20F-A9A6FD2D7DF4

P2860

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

http://www.wikidata.org/entity/Q34147299

description

1994 nî lūn-bûn

@nan

1994 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@ast

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@en

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@nl

type

label

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@ast

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@en

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@nl

prefLabel

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@ast

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@en

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@nl

P1433

Q34147299-9F78BB5D-B0CE-4BF1-93D5-75E5FA9CF33F

P1476

Q34147299-7B734C96-CBA6-47BE-8DED-BEB76767BBBD

P2093

Q34147299-76F70A38-AAB5-4DEF-AB02-9407CF0700EA

Q34147299-93CAA787-38E9-45E6-A972-0724A3EE04C3

Q34147299-988F7FCD-DB60-4B9C-86DB-64B6DE6357E7

Q34147299-FE30A5EE-AB35-4100-9B31-A3738E272DCA

P2860

Q34147299-0473AB4B-7913-4A04-BFCC-F391305F3DBF

Q34147299-08FC4788-0264-4EC3-B2B0-1E60F1A9AC64

Q34147299-0FCD7893-9B66-415C-BDEA-4A7AE01CB521

Q34147299-11503A93-2634-4F88-B96A-0DDF0BFF6BC0

Q34147299-1D518C54-B961-42D8-9BA7-10FD782F2F5F

Q34147299-1E9941DD-35C4-4D35-B5F8-537C7FFEC5A2

Q34147299-2A1EAE01-7830-4A28-95FB-33075C998404

Q34147299-31327DC7-79E7-46DE-A6DA-3248FD19B880

Q34147299-33E7CFE0-1E25-49B4-9B61-BB7B9A35C97A

Q34147299-39181C0B-32A1-4BD9-8474-0A6AC7A6B02F

P304

Q34147299-9B61470A-C298-4485-8298-04A7D9F14BFD

P31

Q34147299-F974F4C3-77F3-49A6-B158-052D78AF888B

P356

Q34147299-B996940A-1A4F-4B29-86D4-BFD4D8F44B40

P407

Q34147299-99FAF2D9-5113-4893-BECA-D6607C5F4919

P433

Q34147299-AAE34A9E-A84D-4D05-B646-047F2C352C72

P478

Q34147299-0720812B-12A0-4876-B8EB-BC8EBCA67336

P577

Q34147299-BD431D27-8C1A-4506-99AF-068AD5AB4D3F

P5875

Q34147299-10B5995A-ECA9-4F23-A08C-CF4511945AE2

P698

Q34147299-E47E0AC0-4156-4E0D-A989-E3996A600723

P921

Q34147299-57d63624-6647-413b-ac0b-84b5620a7a77

Q34147299-A5D0A531-1FB9-4993-ACD2-43796F1757C4

P932

Q34147299-C8A15181-9055-40DE-A776-135C0CB8F82C

P356

P1433

Journal of Clinical Investigation

P1476

Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal

@en

P2093

C R Leusner

http://www.w3.org/2001/XMLSchema#string

D A D'Alessio

http://www.w3.org/2001/XMLSchema#string

J W Ensinck

http://www.w3.org/2001/XMLSchema#string

S E Kahn

http://www.w3.org/2001/XMLSchema#string

P2860

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

Brain metabolism during fasting

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate.

Glucagon and the glucagon-like peptides.

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.

Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones.

Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.

Quantitative estimation of insulin sensitivity.

P304

2263-2266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI117225

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

1994-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15017422

http://www.w3.org/2001/XMLSchema#string

P698

8182159

http://www.w3.org/2001/XMLSchema#string

P921

P932

294382

http://www.w3.org/2001/XMLSchema#string